Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01153906 · ClinicalTrials.gov registry record
Post-marketing Safety Study of Autoimmune Diseases Following Cervarix® Vaccination
A clinical trial, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- 1,516
- Enrollment target
NCT01153906: Completed study, sponsored by GlaxoSmithKline.
NCT01153906 is a clinical trial that has completed, run by GlaxoSmithKline. The registered enrollment target is 1,516 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01153906 has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- 1,516 participants
- Enrollment target
Study Summary
The purpose of this post-marketing study is to evaluate the incidence of autoimmune diseases (AIDs) following females who have received at the least the first dose of Cervarix® as part of their routine health care.
Interventions
- OTHER Data collection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,516 participants |
| Start Date | 2010-10 |
| Est. Completion | 2013-09 |
What the finished NCT01153906 record still lists
NCT01153906 is an observational study that tracks outcomes without assigning an intervention. Its 1,516 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 1 intervention - of which Data collection is the first listed.
NCT01153906 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01153906 about?
NCT01153906 is a clinical study titled "Post-marketing Safety Study of Autoimmune Diseases Following Cervarix® Vaccination". The purpose of this post-marketing study is to evaluate the incidence of autoimmune diseases (AIDs) following females who have received at the least the first dose of Cervarix® as part of their routine health care.
What is the current status of trial NCT01153906?
This trial is currently completed. The enrollment target is 1,516 participants. The study started on 2010-10. Estimated completion is 2013-09.
What interventions are being tested in trial NCT01153906?
The interventions under investigation include: Data collection (OTHER).
Who is sponsoring clinical trial NCT01153906?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05633654 · 1,514 participants · Phase 3
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
- NCT07136623 · 1,513 participants
Detecting Pulmonary Hypertension With the Eko CORE 500 Digital Stethoscope
- NCT07232017 · 1,520 participants
Implementation of Intensive Hypertension Management Approaches: Cleveland Clinic
- NCT06876714 · 1,524 participants · Phase 3
ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia